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Abstract 
Recent research on porous silica materials as drug carriers for amorphous and controlled drug 
delivery has shown promising results. However, due to contradictory literature reports on 
toxicity and high costs of production, it is important to explore alternative safe and inexpensive 
porous carriers.  In this study, the potential of activated carbon (AC) as an amorphous drug 
carrier was investigated using paracetamol (PA) and ibuprofen (IBU) as model drugs. The 
solution impregnation method was used for drug loading, with loading efficiency determined by 
UV spectroscopy and drug release kinetics studied using USP II dissolution apparatus. The 
physical state of the drug in the complex was characterised using differential scanning 
calorimetry and X-ray diffractions techniques, whilst sites of drug adsorption were studied using 
Fourier transform infrared spectroscopy and N2 adsorption techniques. In addition, the 
cytotoxicity of AC on human colon carcinoma (Caco-2) cells was assessed using the MTT assay. 
Results presented here reveal that, for PA/AC and IBU/AC complexes, the saturation solubility 
of the drug in the loading solvent appears to have an effect on the drug loading efficiency and 
the physical state of the drug loaded, whilst drug release kinetics were affected by the wettability 
of the activated carbon particles. Furthermore, activated carbon microparticles exhibited very 
low cytotoxicity on Caco-2 cells at the concentrations tested (10-800 µg/mL). This study, 
therefore, supports the potential of activated carbon as a carrier for amorphous drug delivery. 
Keywords: Activated carbon, Amorphous drug delivery, Paracetamol, Ibuprofen, Oral drug delivery, 
Porous carrier 
Chemical compounds studied in this article 
Paracetamol (PubChem CID: 1983); Ibuprofen (PubChem CID: 3672); Ethanol (PubChem CID: 702); 
Sodium dodecyl sulphate (PubChem CID: 3423265) 
  
  
 
 
1. Introduction 
The effectiveness of an oral dosage form depends on the bioavailability of the drug, which in 
turn depends on its solubility and dissolution rate. However, more than 90% of active 
pharmaceutical ingredients have oral bioavailability issues [1] and about 40% have solubility 
and dissolution limitations [2]. With a limited number of compounds possessing drug like 
properties, it is important to develop effective techniques to improve the solubility and 
dissolution behaviour of poorly water-soluble drugs [3].  
One of the many solubility enhancing techniques includes conversion of a crystalline drug to an 
amorphous form; the dissolution rate of amorphous forms of drugs is markedly better than the 
crystalline form, especially in drugs with high crystal energy [4,5]. The absence of molecular 
order in amorphous forms of drugs allows greater motion of molecules, resulting in higher 
solubility, which plays a crucial role in achieving optimum bioavailability. However, amorphous 
forms have poor stability and often tend to convert back to crystalline forms [6].  
Several studies have been performed to develop stabilising strategies for the amorphous form of 
drugs [7,8], with loading of drugs into porous materials showing great potential [9]; the 
interactions between the carrier and the adsorbed drug, as well as the small pore size of the 
carriers, restricts the crystallisation of the drug. Various types of porous materials have been 
studied as drug carriers for amorphous drug delivery, although there are still many limitations 
hindering the technique, such as complexity of production, low drug loading efficiency, high 
production costs and safety concerns, as highlighted in Table 1. Hence, it is important to explore 
porous materials that can address the aforementioned issues.  
This current study investigates the application of activated carbon (AC) as a drug carrier for 
amorphous drug delivery. AC is inexpensive, commercially available, non-toxic and has a high 
surface area to volume ratio, which can favour development of an effective, inexpensive and safe 
carrier for oral drug delivery. AC is produced from a variety of materials rich in carbon (e.g. 
coal, wood, peat etc.), by either steam activation or chemical activation. Activation develops 
porosity in the carbon and the pore size is affected by the process of activation [28]. AC consists 
of a three-dimensional interconnected pore structure, with micropores (pore width <2 nm), 
mesopores (pore width 2-50 nm) and macropores (pore width >50 nm) [29].  
  
AC is extensively used in drinking water treatment and is also clinically used as an antidote to 
remove poisonings [30–32], whilst several studies have explored its use for various clinical 
applications, as noted in Table 2.  
In this study, the solution adsorption method was used for drug loading in to AC, using 
paracetamol (PA) and ibuprofen (IBU) as model drugs with different saturation solubilities in 
ethanol, in order to determine the effect of solubility on drug loading. 
 
2. Experimental section 
2.1. Materials 
Activated carbon DARCO® G-60 was purchased from Sigma Aldrich, UK. Crystalline 
paracetamol powder was obtained from GlaxoSmithKline, UK. Crystalline ibuprofen powder 
was purchased from SLS, UK. Ethanol, dimethyl sulfoxide, sodium dodecyl sulphate, sodium 
dihydrogen phosphate and disodium hydrogen phosphate were purchased from Fisher, UK. 
Caco-2 cells were purchased from ATCC. Dulbecco’s Modified Eagle’s Medium, foetal bovine 
serum, trypsin-EDTA solution, anti-mycotic solution, Hank’s balanced salt solution, MTT dye, 
phosphate buffered saline and trypan blue were purchased from Sigma Aldrich, UK.  
2.2. Characterisation of activated carbon 
2.2.1. Particle size distribution 
Particle size analysis of activated carbon was performed using laser diffraction (HELOS, 
Sympatec GmbH, Germany). 25 mg of carrier was dispersed in 200 mL of ethanol and was 
analysed for particle size in the measuring range of 0.1 to 500 µm. 
2.2.2. Cell culture and Cytotoxicity assay 
Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, with 4500 mg/L glucose, 
L-glutamine, sodium pyruvate, sodium bicarbonate, amino acids and vitamins) with 10% FBS in 
culture flasks and incubated at 37 °C in an atmosphere of 5% CO2, and the medium was changed 
every 2 days. Cells were sub-cultured when they reached about 60% confluency. Studies were 
performed on cells between passages 100 and 120. 
  
The cell suspension was diluted to achieve a density of 104 cells/mL using DMEM. Cell 
suspension was added to 96 well plates at 100 µL per well, such that each well had a density of 
1000 cells. The cells were incubated for 24 hours. The spent medium was then removed and the 
suspensions with different concentrations of carrier (10-800 µg/mL) were added to 96-well 
plates at 100 µL per well and incubated for a further 24 hours. Caco-2 cells without carrier 
suspension were used as a control. Morphology of cells was observed under light microscope. 
The spent medium was removed after 24 hours of incubation. 100 µL of fresh medium and 20 
µL of 5mg/mL MTT in PBS solution was added to each well and incubated for 4 hours. After 4 
hours, the medium containing MTT was removed and replaced with 100 µL DMSO. The 
absorbance of the resulting formazan solution was determined at 492 nm on a SynergyTM HT 
microplate reader (Biorad, USA).  
2.3. Preparation of drug loaded activated carbon and determination of drug loading 
efficiency 
Solution adsorption is a commonly used method for drug loading in to a porous carrier, where 
the carrier is immersed in a saturated drug solution for a specific duration [39]. In this study, 
drug was dissolved in 10 mL of ethanol to obtain a saturated drug solution at 20 °C (saturation 
solubility of paracetamol and ibuprofen at 20 °C is 190.61 g/kg and 886.5 g/kg of ethanol, 
respectively [40,41]).  1 g of activated carbon was added to the drug solution and the suspension 
was stirred at 25 °C on a hot plate stirrer for 24 hours. The dispersion was centrifuged at 1500 
rpm and the supernatant was collected for further analysis. The sediment was allowed to dry in 
an oven at 40 °C for 24 hours.  
Drug loading efficiency was determined by UV spectroscopy (Jenway, UK). 50 mg of 
drug/carrier complex was added to 50 mL of ethanol and was stirred for 24 hours at 25 °C. The 
solution was filtered and the concentration of the drug in the filtrate was determined.  Loading 
efficiency of activated carbon was calculated using Eq. (1) as follows: 
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2.4. Characterisation of drug loaded activated carbon complex 
2.4.1. Powdered X-ray diffraction (XRD) analysis 
The XRD patterns of the samples were recorded on a D8 ADVANCE diffractometer (Bruker, 
USA) in the angular range of 10° to 50° (2θ) with a step size of 0.02°, using a Cu–Kα source 
operated at 30 kV and 30 mA. 
2.4.2. Differential Scanning calorimetry (DSC) 
Thermal analysis was performed using a Q100 DSC instrument (TA instruments Ltd., UK). 2 
mg of sample was weighed and transferred to a Tzero aluminium pan, with the subsequent 
temperature scan performed at a heating rate of 10 oC/min under N2 gas. Percentage crystallinity 
in the drug loaded carrier was calculated from the melting enthalpy of physical mixture of drug 
and carrier using Eq. (2) [42] : 
                                                            
'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     (2) 
Where +,%= percentage of crystallinity in the drug/carrier complex. +,°% = percentage of 
crystallinity in drug/carrier physical mixture and is considered to be 100. ∆-. = melting 
enthalpy of the drug/carrier complex. ∆-.° = melting enthalpy of drug/carrier physical mixture. 
2.4.3. Fourier transform infra-red spectroscopy (FTIR) 
Spectra were recorded in the range of 500-4000 cm-1 using a Nicolet iS5 spectrometer 
(ThermoFisher Scientific Inc, UK) equipped with iD5 ATR (Attenuated total reflectance) 
accessory with a laminated diamond crystal at an angle of incidence of 42°. The spectra were 
obtained at a spatial resolution of 4 cm-1 and were an average of 16 scans. 
2.4.4. Nitrogen sorption analysis 
Nitrogen adsorption isotherms at 77 K were obtained using an ASAP 2420 (Accelerated surface 
area and porosimetry system, Micrometrics, USA). Activated carbon powder was degassed at 
200 °C for 4 hours and drug containing activated carbon was degassed at 40 °C for 24 hours. 
The specific surface area of the sample was computed using the Brunauer–Emmett–Teller (BET) 
method in the relative pressure range between 0.01 and 0.9. The pore size distribution of the 
sample was calculated using nonlinear density functional theory (NLDFT) method, assuming slit 
shaped pores. 
  
2.4.5. Drug release studies 
Drug release from the complex was studied with a USP Type II dissolution apparatus (Erweka 
GmbH, Germany) using pure crystalline drug (equivalent to the amount of drug in the complex) 
as a control. Sodium phosphate buffer at either pH 5.8 or pH 7.2, with and without 1% w/v 
sodium dodecyl sulfate (SDS), were used as dissolution media for paracetamol and ibuprofen, 
respectively. Dissolution was performed at 37 °C with paddle stirring speed of 100 rpm. 
Samples were withdrawn at specific time intervals and replaced with fresh dissolution medium. 
The samples were filtered using 0.45 µm syringe filters and analysed using UV 
spectrophotometry at wavelengths of 257 nm and 264 nm for paracetamol and ibuprofen, 
respectively. 
2.5. Statistical analysis 
Statistical analysis was carried out on the data by one way ANOVA, using Graph pad prism 
software (Version 6.0 for Windows). Statistically significant differences were denoted for p 
values of less than 0.05. 
 
3. Results and Discussion 
3.1.  Characterisation of activated carbon 
Particle size of the porous carrier is an important characteristic, since, amongst other aspects, it 
may affect the drug release rate; drug loaded in deeper pores of larger particles will need to 
travel a longer distance before release [43]. Also, particle size can affect the cytotoxicity, where 
nanoparticles could result in increased toxicity compared to microparticles due to a higher 
chance of internalisation by cells [23]. However, internalisation of microparticles (0.1-10 µm) by 
endocytosis has also been observed [44,45]. Due to the above reasons, determining the particle 
size and toxicity of activated carbon is crucial. 
AC used in this study has a particle size in the range of 0.55- 87.5µm (Fig.1), with nearly 40% of 
the particles ≤ 10 µm in size, indicating the possibility of internalisation by cells and toxicity. 
Hence, cell cytotoxicity of activated carbon on Caco-2 cells was evaluated by MTT assay. 
Although no significant toxicity was observed for concentrations 10-200 µg/mL, significant 
toxicity was observed for the concentrations ≥ 400 µg/mL (p ≤ 0.05, one way ANOVA and 
Dunnett’s multiple comparison test) as shown in Fig. 2. The slight toxicity at high concentrations 
  
was probably due to adsorption of nutrients in the culture medium by activated carbon particles 
[46,47]. Nevertheless, even at the highest concentration (800 µg/mL) tested, the cell viability 
was still over 80%, suggesting that application of AC with a particle size above 0.55 µm could 
be safe for oral drug delivery. 
3.2. Drug loading into activated carbon  
After 24 hours of drying the sediment obtained from centrifugation (Section 2.3), the 
unloaded/free drug was found to crystallise as a top layer due to the evaporation of the solvent, 
as shown in Fig.3. The top crystalline layer was removed and analysed for drug content, whilst 
the bottom layer was, sieved (mesh 150-opening size 104 µm) to remove any aggregates, 
labelled as drug/carrier complex and analysed for drug loading efficiency (Table 3). During the 
process of removal of the top crystalline layer, an amount of drug loaded activated carbon was 
also removed; therefore, the total amount of activated carbon present in the drug/carrier complex 
is not equal to 1000 mg. 
The higher loading efficiency for ibuprofen (IBU) compared to paracetamol (PA) could be 
attributed to the higher solubility of IBU in ethanol. Although the loading efficiency was higher, 
the fraction of adsorbed to the unadsorbed drug was lower for IBU compared to that of PA, 
which could be due to stronger interactions between IBU and ethanol or due to saturation of AC. 
It was also found that analysis of free drug in the supernatant solution can give a false estimation 
of drug loading capacity, since it does not consider the top crystalline layer of the sediment. 
3.3. Solid state analysis of drug 
DSC and XRD techniques were used to detect crystallinity in the drug/carrier complex. DSC can 
also identify any re-crystallisation of the drug that is initially present in an amorphous state. DSC 
curves for pure drug, activated carbon, drug/carrier complex and drug/carrier physical mixture 
are shown in Fig.4 (a) and (b), whilst melting temperature and melting enthalpy obtained are 
presented in Table 4; the presence of crystalline drug in the drug/carrier complex can be detected 
from the melting peak of crystalline drug. Pure paracetamol and physical mixture exhibited a 
melting peak at 169 °C, characteristic of monoclinic Form I paracetamol [48]. Pure ibuprofen 
and physical mixture exhibited a melting peak at 74.8 °C [49,50], again indicative of crystalline 
drug. For the drug/carrier complexes, no crystalline drug could be detected in PA/AC complex, 
whereas crystallinity was detected in IBU/AC complex, possibly as a consequence of the higher 
drug loading compared to PA/AC complex. Further analysis revealed that the percentage 
  
crystallinity in the IBU/AC complex, which was calculated from the melting enthalpy of 
physical mixture containing an equal amount of drug as the complex, was found to be about 19% 
of the total drug present in the IBU/AC complex. These results suggest that using a saturated 
drug solution for loading is not suitable for all drugs, especially for drugs with high solubility in 
the respective solvent, and could result in increased crystallinity and reduced uniformity in the 
drug/carrier complex. Hence, it is important to determine the optimum concentration required in 
the loading solution for each drug to obtain drug/carrier complexes with no drug crystallinity. 
Also, it was observed that the melting enthalpy of the drug in the physical mixture was lower 
than that of the pure drug, which could be attributed to the interactions between AC surface and 
the drug undergoing the melting process, leading to reduced intermolecular forces in the drug 
[51,52]. Reduction of enthalpy could also be due to adsorption of drug in to the pores of AC 
during the process of melting, although the reasons behind this would require further 
investigation. 
The DSC results were also supported by X-ray diffraction studies (Fig.5). XRD patterns of pure 
IBU and IBU/AC physical mixture samples (Fig.5 (a)) showed characteristic peaks at 11.8°, 
16.4°, 17.4°, 20° and 22° (2θ), suggesting the highly crystalline nature of IBU [53,54]. IBU/AC 
complex also showed a diffraction pattern corresponding to crystalline IBU; however, the peaks 
at 20° and 22° were less intense, suggesting reduced crystallinity of IBU. XRD patterns (Fig. 5 
(b)) of PA and PA/AC physical mixture samples showed characteristic peaks corresponding to 
crystalline PA at 15.4°, 18.1°, 20.3°, 23.3°, 24.2° and 26.4° [55]. No XRD pattern corresponding 
to crystalline PA could be detected in the case of PA/AC complex, supporting the DSC results, 
suggesting that the PA is completely present in an amorphous form, which indicates that PA is 
effectively loaded in to the pores of AC. However, with IBU/AC complex, crystallinity (19%) 
was detected, which indicates that IBU is not completely loaded in to the pores of AC and could 
be present as separate crystals. From the UV analysis, loading efficiency for IBU was found to 
be 44.4 %, whilst from DSC, 19% of the drug loaded was found to be crystalline, which is 
equivalent to 122 mg of IBU (total amount of drug in the complex was 643 mg, as shown in 
Table 3). Therefore, in order to determine the theoretical loading efficiency of IBU into the 
pores of AC in amorphous state, the amount of crystalline IBU is subtracted from the total IBU 
loaded, which was determined to be 39%, suggesting that IBU/AC complex with loading higher 
than this could result in crystallisation of IBU. As such, IBU/AC complex with completely 
  
amorphous drug may be achieved by reducing the concentration of IBU in the loading solution, 
thereby avoiding overloading, although this would require further investigation.  
3.4. Sites of drug adsorption 
Drug deposited on the external surface of AC can pose a risk of re-crystallisation during storage; 
as such, FTIR was used to detect any unloaded drug particles or drug deposited on the surface of 
AC. FTIR spectra of pure drug, drug/carrier physical mixture, and carrier and drug/carrier 
complex are shown in Fig. 6 (a) and (b). The sloping of spectra in samples containing AC is due 
to an increase in the absorption by carbon at lower wavenumbers, since the depth of penetration 
increases at lower wavenumbers [56]. Spectra of paracetamol and physical mixture showed 
peaks corresponding to an NH amide band stretch at 3320 cm-1 and a broad phenolic OH stretch 
at 3129 cm-1. No significant peaks corresponding to PA were found in the case of PA/AC 
complex (Fig. 6 (a)). Since the depth of penetration of IR in to the samples is only about 0.2-5 
microns, drug deposited in the deeper pores may not be detected [57], which suggests that the 
paracetamol was loaded in the pores of activated carbon and was absent on external surface of 
the particles. However, with IBU/AC complex, peaks corresponding to carbonyl CO stretch at 
1694 cm-1 can be detected, similar to the pure IBU and physical mixture (Fig. 6 (b)), which 
could be due to the presence of IBU as separate drug crystals or drug adsorbed on the external 
surface. Results from FTIR studies support the DSC and XRD data, that the drug in PA/AC 
complex is completely present in the pores of AC in a stable amorphous state. However, in the 
case of IBU/AC complex, drug is present outside the pores, either deposited on the external 
surface of AC or as separate crystals. 
3.5. In vitro drug release studies 
In vitro drug release from the complex was studied using the paddle type dissolution apparatus. 
Drug release profiles for pure drug and drug/carrier complex are shown in Fig. 7 (a) and (b). 
Unfavourably, only 54 ± 2.8% (PA/AC) and 61 ± 3% (IBU/AC) of the total drug loaded was 
released from the drug/carrier complex in sodium phosphate buffer within 10 mins, after which 
no further drug release was observed. Incomplete drug release from the complex could be due to 
poor wettability of carbon particles (powder samples floating on the surface of the dissolution 
medium could be observed). Hence, 1% SDS was added to the dissolution medium to prevent 
floating of powders; in the presence of SDS, complete drug release was achieved within 10 min 
for both drug loaded complexes. Indeed, the release rate was higher for PA/AC complex 
  
compared to the pure drug, whereas no marked difference was observed for IBU/AC complex, 
which could be due to the faster release of pure IBU. Both drug loaded complexes in SDS 
showed complete drug release within 10 minutes irrespective of their individual release rates 
(Pure PA and Pure IBU in the presence of SDS achieved complete release within 20 min and 15 
min, respectively), which could be due to the stronger influence of the porosity of the AC on the 
dissolution profiles compared to the drug characteristics, although this would require further 
investigation to elucidate the mechanisms involved. Compared to the pure crystalline drug, a 
higher initial release or a burst effect (with and without SDS) and faster complete release (with 
SDS) were observed for both drug loaded complexes, which could be due to release of drug 
from superficial pores and the amorphous nature of the drug, respectively. Compared to pure 
drug, amorphous drug present in the pores of AC has a higher surface area in contact with the 
dissolution media, which can result in faster release; thus, the drug loaded in to AC, compared to 
the pure crystalline drug, favoured faster release. 
3.6. Porosity analysis of carrier before and after drug loading 
Adsorption isotherms and pore size distribution curves are shown in Fig. 8 (a & b), with the data 
from N2 sorption studies summarised in Table 5. The adsorption/desorption isotherm of AC 
exhibited a typical type IV isotherm, with a hysteresis loop characteristic of microporous 
materials with significant mesoporosity [58]. Unloaded activated carbon particles showed higher 
surface area and pore volume compared to drug/carrier complex, demonstrating the pore filling 
by drug molecules in both PA and IBU loaded AC samples. Although the amount of drug loaded 
in PA/AC complex was markedly lower (Table 3), total pore volume was only slightly higher 
compared to IBU/AC complex, which could indicate the presence of surface adsorbed or 
separate, non-associated crystals of IBU. The pore size distribution of pure AC shows the 
presence of pores in the range of 2-14 nm. Post loading, a reduction in pore size was observed 
for PA/AC complex, but the general characteristics of pure AC were retained. However, in the 
case of IBU/AC complex, pores with size > 6 nm were greatly reduced, which could be due to 
the reduction of pore size from higher drug loading.  
 
4. Conclusion and perspective   
Paracetamol and ibuprofen were successfully loaded in to activated carbon, with a drug loading 
of 20.7 ± 1 % and 44.4 ± 4 % (w/w) achieved for PA and IBU, respectively. PA loaded in to 
activated carbon was completely amorphous, whereas 19% of the IBU loaded in to activated 
  
carbon was found to be crystalline, suggesting that the true loading efficiency for amorphous 
IBU is only 39%. FTIR studies suggested the absence of surface adsorbed drug in PA/AC 
complex, whereas surface adsorbed drug or separate drug crystals were detected in IBU/AC 
complex. The higher loading of IBU and presence of crystallinity in the IBU/AC complex could 
be due to higher concentration of IBU in loading solution, supporting the theory that the 
chemical nature of the drug has an effect on the loading efficiency, and the use of a saturated 
drug solution for drug loading cannot always be recommended. In vitro release studies suggested 
that drug release was complete within 10 min (in the presence of 1% SDS) for both PA/AC 
complex and IBU/AC complex. The release rate of drug/carrier complex was independent of the 
characteristic release rate of the pure drug. The low toxicity, high drug loading capacity and 
ability to stabilise amorphous drug supports the potential of activated carbon as an amorphous 
drug carrier. 
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Figures  
 
Material X90a (µm) X50b (µm) X10c (µm) Volume mean 
diameter (µm) 
Span 
Activated 
carbon 
40.59 ± 0.53 12.62 ± 0.09 3.92 ± 0.02 17.85 ± 0.15 2.91 ± 0.02 
 
a
 Particle dimension corresponding to 90% of the cumulative undersize distribution 
b Median particle dimension 
c
 Particle dimension corresponding to 10% of the cumulative undersize distribution 
 
Fig. 1. Particle size distribution of activated carbon obtained from laser diffraction. 
  
 
Fig. 2. Cytotoxicity of activated carbon against Caco-2 cells. MTT assay was used to analyse the 
survival rate of Caco-2 cells incubated with different concentrartions of activated carbon. 
Statistically significant differences compared to control (0 µg/mL) are noted for P < 0.05 (*P ≤ 
0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001, one way ANOVA and Dunnett’s multiple 
comparison test). 
 
 
 
Fig. 3: Photographic image of drug/carrier complex and crystallised drug obtained after drying 
the sediment obtained from centrifugation. Top white crystalline layer is separated and the 
bottom layer is considered as drug/Carrier complex for further analysis. 
 
0
1
0
4
0
1
0
0
2
0
0
4
0
0
6
0
0
8
0
0
  
 
Fig. 4: DSC curves of (a) pure ibuprofen (IBU), pure activated carbon (AC), ibuprofen loaded 
activated carbon sample (IBU/AC complex) and physical mixture of ibuprofen and activated 
carbon (IBU/AC phy mix) (b) pure paracetamol (PA), pure activated carbon (AC), paracetamol 
loaded activated carbon sample (PA/AC complex) and physical mixture of paracetamol and 
activated carbon (PA/AC phy mix).  
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Fig. 5: XRD patterns of (a) pure ibuprofen (IBU), pure activated carbon (AC), ibuprofen loaded 
activated carbon sample (IBU/AC complex) and physical mixture of ibuprofen and activated 
carbon (IBU/AC phy mix) (b) pure paracetamol (PA), pure activated carbon (AC), paracetamol 
loaded activated carbon sample (PA/AC complex) and physical mixture of paracetamol and 
activated carbon (PA/AC phy mix). 
  
 
 
Fig. 6: FTIR spectra of (a) pure paracetamol (PA), pure activated carbon (AC), paracetamol 
loaded activated carbon sample (PA/AC complex) and physical mixture of paracetamol and 
activated carbon (PA/AC phy mix) (b) pure ibuprofen (IBU), pure activated carbon (AC), 
ibuprofen loaded activated carbon sample (IBU/AC complex) and physical mixture of ibuprofen 
and activated carbon (IBU/AC phy mix).                             
%
	T
ra
n
sm
it
ta
n
ce
  
                    
 
Fig. 7: Comparison of cumulative drug release from pure drug and drug loaded carrier samples 
at 37°C using paddle type dissolution apparatus. (a) Curves PA and PA/AC complex represent 
pure paracetamol and paracetamol loaded activated carbon samples in sodium phosphate buffer 
(pH 5.8). Curves PA-SDS and PA/AC complex-SDS represents pure paracetamol and 
paracetamol loaded activated carbon samples in sodium phosphate buffer (pH 5.8) containing 
1% SDS. (b) Curves IBU and IBU/AC complex represent pure ibuprofen and ibuprofen loaded 
activated carbon samples in sodium phosphate buffer (pH 7.2). Curves IBU-SDS and  IBU/AC 
  
complex-SDS represent pure ibuprofen and ibuprofen loaded activated carbon samples in 
sodium phosphate buffer (pH 7.2) containing 1% SDS. 
 
  
 
 
Fig. 8: (a) Nitrogen adsorption/desorption isotherms at 77 K (b) Pore size distribution (2-14nm) 
calculated using NLDFT-slit shaped pore model, of pure activated carbon (AC), ibuprofen 
loaded activated carbon (IBU/AC complex) and paracetamol loaded activated carbon (PA/AC 
complex).  
  
 
Tables 
 
Table 1: Porous materials studied as carriers for amorphous drug delivery 
Porous 
material 
Surface 
area 
Synthesis Advantages Limitations Reference 
Porous 
silicon 
Up to 
1000 m2/g 
 
Electrochemical 
etching 
Biodegradable 
Ease of synthesis 
Ease of fabrication  
Undergoes atmospheric oxidation  
Requires surface modification for stability 
Possible chemical interactions with drugs  
 
[10–13] 
Non 
ordered 
porous 
silica 
Up to 800 
m
2/g 
Sol-gel process Ease of synthesis  Surface silanol groups can chemically interact with carboxyl 
groups of drugs via hydrogen bonding or esterification and can 
pose risk of irreversible drug adsorption or slower drug 
release, which can be disadvantageous if immediate release is 
preferred 
Siloxane bridges might undergo hydrolysis 
 
[12,14–19] 
Ordered 
mesoporous 
silica 
(OMS) 
Up to 
1200 m2/g 
Surfactant 
templating 
Uniform porosity 
Large surface area  
 
Complicated and expensive synthesis  
Variable Toxicity results 
Chemical interactions between surface silanol groups and 
drugs, as with non ordered porous silica 
Siloxane bridges might undergo hydrolysis 
[12,20–23] 
Ordered 
mesoporous 
carbon 
Up to 
1400 m2/g 
Hard templating 
method 
Uniform porosity 
Large surface area 
Chemically Inert 
Insoluble in biological 
fluids  
Synthesis involves use of OMS as template 
Poor wettability 
[24–27] 
  
  
 
 
Table 2: Potential clinical applications of activated carbon 
Potential applications Result Reference 
 
Chemotherapy 
Drugs adsorbed on to AC nano particles were 
selectively delivered to regional lymph nodes and 
retained at the site of injection for a longer duration in 
rats and cancer patients. 
[33] 
 
Antacid 
Calcium carbonate or sodium carbonate adsorbed on 
the activated carbon was able to maintain ideal pH and 
neutralize gastric acidity without any rebound effect in 
vitro. 
[34,35] 
 
Photo thermal cancer 
therapy 
When exposed to laser radiation, PVP dispersed AC 
nano particles were able to convert light in to heat 
energy and resulted in tumour growth suppression at 
the site of injection in mice.  
[36] 
 
Lymph node staining 
AC of particle size < 200 nm injected was readily 
absorbed in to regional lymphatics and blackened 
lymph nodes.  
[37] 
 
Controlled release 
AC containing temperature responsive hydrogel was 
used to increase the drug loading capacity and 
mechanical strength of the hydrogel for controlled 
release.  
[38] 
 
 
 
 
  
 
Table 3: Comparison of ibuprofen and paracetamol loading in activated carbon 
Drug Initial quantity 
of drug a (mg) 
Quantity of drug  in 
complex (mg) 
% Loading 
efficiency  
Quantity of drug in (mg) 
Supernatant b Crystalline 
layer c 
PA 1500 208 ± 12.5 20.7 ± 1 985.5 ± 12 320.5 ± 6 
 
IBU 6900 643 ± 77.7 44.4 ± 4 5592.4  ± 159 662.3 ± 174 
 
a
 per 10 mL of Ethanol 
b
 obtained from centrifugation 
c  top crystalline layer of the sediment after drying. 
  
  
Table 4: Melting Enthalpy and Melting points obtained from differential scanning calorimetry of pure ibuprofen (IBU), pure activated carbon 
(AC), ibuprofen loaded activated carbon sample (IBU/AC complex) and physical mixture of ibuprofen and activated carbon (IBU/AC phy 
mix), pure paracetamol (PA), paracetamol loaded activated carbon sample (PA/AC complex) and physical mixture of paracetamol and 
activated carbon (PA/AC phy mix). 
Sample Drug carrier 
ratio (w/w) 
Melting 
Enthalpy (J/g) 
Melting 
temperature (°C) 
% Crystallinity  
IBU 1:0 130.3 74.8 100 
IBU/AC phy mix 0.8:1 83.4 74.8 100 
 
IBU/AC complex 0.8:1 15.78 72 19 
PA 1:0 181 169.2 100 
PA/AC phy mix 0.25:1 27.1 169.2 100 
PA/AC complex 0.25:1 - - 0 
 
 
 
Table 5: Surface areas and pore volumes obtained from Nitrogen sorption of pure activated carbon (AC), ibuprofen loaded activated carbon 
(IBU/AC complex) and paracetamol loaded activated carbon (PA/AC complex)  
Sample Specific surface areaa 
(m2/g) 
Total pore volume b 
(cm3/g) 
Micro pore volume b 
(cm3/g) 
AC 1027.4 0.81 0.33 
PA/AC complex 127 0.31 0.016 
IBU/AC complex 101.8 0.23 0.014 
 
  
a
 Calculated  by BET method 
b Calculated by NLDFT method  
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